drugset / Trial / NCT02099175
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Phase 2
Unknown
41 enrolled
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Regione Lombardia · collab
NaSingle-groupOpen-labelTreatment
Summary
Sinonasal tumors are rare diseases, so no standard treatment for such aggressive tumors has been reported, given rarity, absence of prospective study and heterogeneity of histologies and stages of diseases. This study proposes innovative integration of multiple modality of treatment depending by histology, molecular profile and response to induction CT. Moreover, such strategies allows the use of latest technology with greater biological effectiveness and reduction of toxicities.
Timeline
- Start
- 2013-11
- Primary completion
- 2020-01
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 33 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 3000 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 250 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 800 mg/m2 | Intravenous |